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A B S T R A C T
The aim of this study is to investigate using nanoemulsion formulations as drug-delivery vehicles of
paclitaxel (PX), a poor water-soluble anticancer drug. Two commercially available nanoemulsion fat
formulations (Clinoleic 20% and Intralipid 20%) were loaded with PX and characterised based on their
size, zeta potential, pH and loading efﬁciency. The effect of formulation on the cytotoxicity of PX was also
evaluated using MTT assay.
The droplet size of the Clinoleic emulsion increased from 254.1 nm to 264.7 nm when paclitaxel (6 mg/
ml) was loaded into the formulation, compared to the drug-free formulation. Similarly, the droplet size of
Intralipid increased from 283.3 to 294.6 nm on inclusion of 6 mg/ml paclitaxel. The Polydispersity
Indexes (PDIs) of all the nanoemulsion formulations (Clinoleic and Intralipid) were less than
0.2 irrespective of paclitaxel concentration indicating that all nanoemulsion formulations used were
homogeneously sized. The pH range for the Clinoleic formulations (7.1–7.5) was slightly higher than that
of the Intralipid formulations (6.5–6.9). The zeta potential of linoleic had a greater negative value than
that of Intralipid.
Loading efﬁciencies for paclitaxel were 70.4–80.2% and 44.2–57.4% for Clinoleic and Intralipid
formulations, respectively. Clinoleic loaded with paclitaxel decreased the viability of U87-MG cell to
6.4  2.3%, compared to Intralipid loaded with paclitaxel (21.29  3.82%). Both nanoemulsions were less
toxic to the normal glial cells (SVG-P12), decreasing the cell viability to 25–35%. This study suggests that
nanoemulsions are useful and potentially applicable vehicles of paclitaxel for treatment of glioma.
ã 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Paclitaxel (PX) is widely used for its anticancer activity against
ovarian carcinoma, head and neck cancers, breast cancer, lung
cancer and AIDS related Kaposi’s sarcoma (Rowinsky and
Donehower, 1995). However, the clinical use of paclitaxel is
limited because of its poor water-solubility as well as low cellular
permeability (Panchagnula, 1998; Singla et al., 2002; Wani et al.,
1971; Yoshizawa et al., 2014). For clinical administration, paclitaxel
is dissolved in Cremophor1 EL (Poly-oxyethylated castor oil) and* Corresponding authors.
E-mail addresses: mohammad.najlah@anglia.ac.uk, m_najlah@yahoo.co.uk
(M. Najlah), aelhissi@qu.edu.qa, aelhissi@yahoo.com (A.M.A. Elhissi).
http://dx.doi.org/10.1016/j.ijpharm.2016.04.027
0378-5173/ã 2016 The Authors. Published by Elsevier B.V. This is an open access articlethanol (50:50 v/v) followed by dilution by 5–20 times before
parenteral administration. The commercially established formula-
tion of Cremophor1 EL-based paclitaxel is “Taxol1”. Unfortunately,
this formulation causes serious toxic effects such as nephrotoxici-
ty, hypersensitivity reactions, neurotoxicity, laboured breathing,
hypotension and lethargy (Singla et al., 2002). Therefore, a
biocompatible formulation that can increase aqueous solubility
and improve therapeutic efﬁcacy of the drug is needed (Kadam
et al., 2014). For example, clinical trials have demosnstrated that
Abraxane1, a formulation of paclitaxel loaded onto albumin
nanoparticles can provide enhanced penetration of the anticancer
drug in the tumour by 33% compared to Taxol1 (Garber, 2004).
However, as human albumin is used in this formulation, designing
alternative nanomedicines that are safe and economically afford-
able is highly desirable. There has been growing interest in usinge under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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liposomal paclitaxel in a rat brain tumour model increased the life
span of the animals up to 40% compared to cremophor EL and
ethanol mixture formulations of paclitaxel (Zhou et al., 2010).
Lipusu1 (Luye Pharma Group) is a paclitaxel-liposomal formula-
tion that has recently been commercialized and recommended for
the treatment of breast, ovarian and non-small cell lung cancer
(Koudelka and Turánek, 2012; Wang et al., 2013).
Recently, nanoemulsion formulations have been used as
delivery vehicles for paclitaxel and docetaxel. Paclitaxel readily
dissolves in the dispersed lipid phase and can easily be
administered intravenously due to the continuous aqueous phase
(Choudhury et al., 2014a; Pawar et al., 2014). Early reports have
shown that lipid nanoemulsions licensed as parenteral nutrition
(PN) (e.g. Intralipid1) are potentially applicable solubilizers of
lipophilic anticancer drugs. This was achieved by using a cosolvent
(e.g. ethanol) to dissolve the anticancer drug followed by addition
to the nanoemulsion. Following in vivo studies, these formulations
were reported to be suitable for human administration (Fortner
et al., 1975; Ames and Kovach, 1982). Recently, we have used
licensed nanoemulsionsas delivery vehicles for paclitaxel. Howev-
er, to avoid the irritant effect of the colsolvent ethanol, loading of
the drug into the emulsion droplets was assisted by the use of bath
sonication (Kadam et al., 2014).
In this study, two commercially available lipid nanoemulsions
that are routinely used in parenteral nutrition (PN)/total parenteral
nutrition (TPN) were used to solubilize paclitaxel for application on
glioma cell lines. Intralipid (Fresenius Kabi, Germany) and
ClinOleic (Baxter, USA) are lipid nanoemulsions having different
excipients. Our research group has shown that both these
nanoemulsions are suitable for solubilizing the highly hydrophobic
antifungal drug amphotericin B and that such formulations can
generate inhalable aerosols by air-jet nebulization (Nasr et al.,
2012). Intralipid is composed of egg phospholipid, soybean oil and
glycerine, while Clinoleic comprises reﬁned olive oil and soybean
oil (Table 1). Recently, we reported the short-term stability of
paclitaxel-loaded Clinoleic1 and Intralipid1 nanoemulsions when
stored at room temperature and at 4 C. On storage for 14 days,
paclitaxel-loaded nanoemulsions were more stable at 4 C than at
room temperature, and the Clinoleic formulations were more
stable than the Intralipid emulsions, having smaller droplet size,
and pH values closer to that of blood plasma (Kadam et al., 2014).
In this study, the physicochemical properties of paclitaxel-
loaded nanoemulsions of Clinoleic1 and Intralipid1 such as size
distribution and zeta potential of the emulsiﬁed droplets, pH of the
formulations, and drug entrapment efﬁciency of paclitaxel in the
lipid phase were studied. Moreover, the cytotoxicity of the
formulations on grade IV glioma (U87-MG) and normal glial
(SVG-P12) cell lines was investigated.
2. Materials and methods
2.1. Materials
Dextran (MW 5000), dimethyl sulfoxide (DMSO), Phosphate
buffered saline (PBS), poly-L-lysine (PL; MW 70,000), sodiumTable 1
Compositions of the Clinoleic and Intralipid emulsions.
Clinoleic TPN (100 ml) 
 Reﬁned olive oil (approx. 80%) and reﬁned soybean oil (approx. 20
 Puriﬁed egg phospholipids 1.2 g 
 Glycerol 2.25 g 
 Essential fatty acids 4 g
 Sodium oleate 0.03 gpyruvate and trypan blue were all purchased from Sigma Aldrich,
UK. Trypsin-EDTA (Ethylenediaminetetraacetic acid) solution,
absolute ethanol, 70% ethanol and HPLC-grade water were
supplied by Fisher Scientiﬁc, UK. Eagle’s minimum essential media
(EMEM), non-essential amino acid solution (100x) and L-gluta-
mine (2 mM) were purchased from Lonza, Switzerland. The
anticancer drug paclitaxel was obtained from Sigma Aldrich, UK
and the parenteral nutrition emulsions, Clinoleic 20% and Intra-
lipid 20% were supplied by Baxter Healthcare, USA and Fresenius
Kabi, Germany respectively. The U87-MG (grade IV glioma cell
lines) and SVG-P12 (normal glial cell lines) were supplied by the
European Collection of Cell Cultures (ECACC).
2.2. Methods
2.2.1. Solubilization of paclitaxel in PN nanoemulsions
Paclitaxel was weighed in amounts of 0 (blank), 10, 20, 30, 40,
50 and 60 mg in separate glass vials. 10 ml of Clinoleic or Intralipid
emulsions were added to each glass vial followed by vortex-mixing
for 5 min and bath sonication for 2 h at 40 C. Preliminary results
showed that there was no effect of bath sonication on the stability
of emulsions (data not shown).
2.2.2. Particle size and zeta potential analysis of nanoemulsions
Photon correlation spectroscopy (dynamic light scattering) was
used to analyse the size distribution of nanoemulsions by
employing the Zetasizer Nanoseries instrument (Malvern Instru-
ments Ltd, UK). Clinoleic or Intralipid nanoemulsions (40 ml)
(without any ﬁltration) were diluted with 1 ml HPLC-grade water
in a clean Malvern sample vial, and the hydrodynamic diameter
and polydispersity index (PI) of the emulsion droplets were
measured. The same instrument was employed to analyse the zeta
potential of the emulsions, by laser Doppler velocimetry, by
operating the relevant software. The zeta potential cuvette
(Malvern Instruments Ltd, UK) was washed several times with
HPLC water prior to loading the nanoemulsion samples and
measuring the zeta potential values of the different formulations.
2.2.3. pH determination of nanoemulsions
The pH of emulsion formulations was determined using a
Corning 220 pH meter (Cole-Palmer, Teddington, UK) previously
calibrated using the provided pH 4 and pH 7 solutions. This
experiment aimed to investigate the inﬂuence of nanoemulsion
type and paclitaxel concentration on the pH, and compare the
values with those of blood plasma.
2.2.4. Loading efﬁciency of paclitaxel in nanoemulsion droplets
Entrapment efﬁciency of paclitaxel was determined by adapting
the separation methods previously described by Kumar et al.
(2001) and Gala et al. (2015). The nanoemulsion formulations
containing paclitaxel (10, 30 and 60 mg per 10 ml) were ﬁltered
through a 0.4 mm pore-size syringe ﬁlter (Fisher Scientiﬁc, UK). The
ﬁlter was washed with HPLC water until the solution ran clear. The
ﬁlter was then placed in absolute ethanol and paclitaxel was
extracted. The extracted fraction was collected to determine the
proportion of un-entrapped drug by measuring the absorbance inIntralipid TPN (100 ml)
%) 20 g  Reﬁned soybean oil 20 g
 Puriﬁed egg phosphatides 1.2 g
 Glycerol anhydrous 2.2 g
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7315 Spectrophotometer, UK). This amount was subtracted from
the total amount of paclitaxel in the formulation to calculate the
amount of entrapped drug. The solubility of paclitaxel in water is
less than 0.1 mg/ml (Konno et al., 2003), therefore, the amount of
the drug dissolved in water during hydration was negligible. The
loading efﬁciency (LE) of paclitaxel (PX) in nanoemulsion was
calculated using the following equation:
EE %ð Þ ¼ Amount of PX entrapped
Total amount of PX in nanoemulsion formulation
 100
2.2.5. Cytotoxicity study (MTT assay)
The U87-MG cells (grade IV glioma, passage 28–31) and SVG-
P12 (glial cells, passage 15–18) were seeded at 1 105 cells/well in
96-well plates and maintained at 37 C in an atmosphere of 5% CO2
and 95% relative humidity in Eagle’s minimum essential medium
(EMEM) supplemented with 10% FBS, 1 mM sodium pyruvate,Fig. 1. (a) Size (Zaverage) and (b) PI of Clinoleic and Intralipid nanoem2 mM L-glutamine and 0.1 mM non-essential amino acids. After
24 h incubation, the cells were washed in PBS solution, and 200 ml
of tested formulations at a range of concentrations was added.
Prior to assay, both loaded nanoemulsions of 1 mg/ml were ﬁltered
through a 0.4 mm sterile syringe ﬁlters to avoid contamination and
to remove unloaded paclitaxel. Resulting ﬁltered nanoemulsions of
paclitaxel concentrations of 0.704 and 0.570 mg/ml for Clinoleic
and Intralipid, respectively (Fig. 4), were used as stock nano-
emulsions diluted by media to 1, 2.5, 5, 25, 50, 250, 500, 1500,
3000 nM of loaded paclitaxel. Additionally, drug-free nanoemul-
sions and paclitaxel alone (i.e. without emulsions, in similar
concentrations range to that of loaded drug) were applied on the
cells. Poly-L-lysine (PLL) and dextran were used as positive control
and negative controls respectively (Fig. 5). Traces of dimethylsulf-
oxide (DMSO) (up to 0.3%) were used to solubilise free paclitaxel in
cell culture medium. After 72 h incubation at 37 C, 20 ml of 3-(4,5-
dimethythiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution (5 mg/ml) was added and cells were incubated for aulsion droplets at a range of paclitaxel concentrations (n = 3  SD).
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and incubated for 30 min at 37 C. The optical density at 570 nm
was measured (Tecan GENios Plus, Switzerland), and the level of
colour development in the control wells (containing medium only)
was taken to indicate 100% viability). The IC50 values (i.e.
concentration resulting in 50% inhibition of cell growth) of the
nanoemulsions and paclitaxel were calculated graphically from the
cell-viability curves obtained by considering the absorbance of the
media containing cells as 100% (Yang et al., 2007).
2.2.6. Statistical analysis
All experiments were performed three times using three
different batches and the results are presented as the mean  SD.
The student’s t-tests and one-way ANOVA tests were performed
using SPSS 14.0 software to calculate the signiﬁcance between the
groups. The differences were considered to be statistically
signiﬁcant if the P-value was less than or equal to 0.05.
3. Results and discussion
3.1. Size distribution of nanoemulsion droplets
The droplet size of the nanoemulsions was dependent on both
emulsion type and paclitaxel concentration in the formulations
(Fig. 1a). The mean size of the Clinoleic emulsion droplets was
signiﬁcantly smaller than Intralipid droplets (P < 0.05) regardless
of paclitaxel concentration (Fig. 1a). Moreover, increasing the
concentration of paclitaxel caused a signiﬁcant increase in the
mean droplet size (P < 0.05) for both emulsions. Fig. 1a shows that
droplet size of the Clinoleic emulsion increased from 254.1 nm
when no drug was included to 264.7 nm when the drug
concentration was 6 mg/ml, whilst for Intralipid, the mean droplet
size was 283.3 nm without drug and 294.6 nm with 6 mg/ml
paclitaxel.
All nanoemulsion formulations had polydispersity index (PI)
values below 0.2, regardless of emulsion type and paclitaxel
concentration (Fig. 1b). Particles may be considered monodis-
persed if the PI is less than 0.2 (Bernardi et al., 2011). The
monodisperse size distribution of paclitaxel nanoemulsions in this
study suggests that paclitaxel has been predominantly accommo-
dated in the bulk of the oil droplets.
Similar to droplet size results, for each paclitaxel concentration
the PI was signiﬁcantly lower (P < 0.05) for the Clinoleic nano-
emulsion compared to the Intralipid formulation. Furthermore,
loading paclitaxel resulted in a signiﬁcant increase (P < 0.05) of PI
for both nanoemulsions and this was greater for the Intralipid
emulsion (Fig. 1b). For instance, compared with the drug-free
nanoemulsions, inclusion of paclitaxel (6 mg/ml) caused aFig. 2. pH of Clinoleic and Intralipid formulations at signiﬁcant increase (P < 0.05) in the PI by 16.6% for the Clinoleic
droplets and 39.25% for the Intralipid formulation. It is noteworthy
that in the preliminary experiments, ﬁltered samples of both
nanoemulsions (through 0.4 mM ﬁlters) were compared with
unﬁltered samples in terms of size, pH, and zeta potential. There
were no signiﬁcant differences between ﬁltered and unﬁltered
nanoemulsions in terms of size, pH and zeta potential (data not
shown). This might indicate that unloaded paclitaxel had no
impact on the droplets size and polydispersity of both nano-
emulsions.
The difference in mean size and polydispersity between the two
types of nanoemulsion is attributed to the difference in formula-
tion composition (Table 1), where the additional surfactant in the
Clinoleic emulsion (i.e. sodium oleate) seems to be better than
phospholipid in the Intralipid formulation at making the droplets
smaller even when paclitaxel concentration was as high as 6 mg/
ml.
3.2. pH of nanoemulsions
The pH values for the nanoemulsions of Clinoleic formulations
were slightly basic, while the Intralipid formulations were slightly
acidic, regardless of paclitaxel concentration (Fig. 2). For both
nanoemulsion types, the inﬂuence of paclitaxel concentrations on
the measured pH was not signiﬁcant (P > 0.05) indicating that these
paclitaxel-loaded nanoemulsions would be potentially appropriate
for intravenous administration. The combination of a clinically
approved anticancer drug namely paclitaxel and clinically
established PN nanoemulsions suggests these formulations are
particularly appropriate for future in vivo investigations for the
treatment of cancer.
3.3. Surface charge of nanoemulsion droplets
The zeta potential of the droplets of Clinoleic had higher
negative charge than that of the Intralipid emulsion, regardless of
paclitaxel concentration (p < 0.05; Fig. 3). The zeta potential of the
Intralipid emulsions was almost neutral, particularly at paclitaxel
concentrations between 2 and 6 mg/ml (Fig. 3). Overall, the zeta
potential was dependent (p<0.05) on emulsion type rather than
paclitaxel concentrations (P>0.05 for both emulsions), indicating
that the surface charge of these emulsions was determined by
emulsion excipients rather than paclitaxel incorporation i.e.
paclitaxel is incorporated in the bulk of droplets.
It has been previously reported that zeta potential of nano-
emulsion formulations depends on the pH of the preparation. If the
pH is high (i.e. basic pH) the zeta potential value is likely to be
negative whilst if the pH is low (i.e. acid pH) the zeta potential willa range of paclitaxel concentrations (n = 3  SD).
Fig. 3. Zeta potential of droplets in Clinoleic and Intralipid nanoemulsion formulations at a range of paclitaxel concentrations (n = 3  SD).
Fig. 4. (a) Loading efﬁciency of paclitaxel in Clinoleic and Intralipid nanoemulsions and (b) paclitaxel loaded per ml of the nanoemulsion (n = 3  SD).
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negative zeta potential of the Clinoleic emulsion is possibly
attributed to its higher pH (Fig. 3). For a nanoemulsion to be
electro-statically stable, so that it is not susceptible to coalescence
during storage, the zeta potential values should be close to or above
30 mV (Elsheikh et al., 2012). Short-term (two weeks) stability
studies in our laboratory indicated that these paclitaxel-loaded
nanoemulsions are stable if stored at 4 C, but not at room
temperature (Kadam et al., 2014). Long-term stability studies are
still needed in the future to evaluate the effect of paclitaxel loading
on the stability of Clinoleic and Intralipid nanoemulsions.Fig. 5. Viability of (a) SVG-P12 and (b) U87-MG cell lines with increasing 3.4. Loading efﬁciency of paclitaxel in nanoemulsion droplets
Loading was calculated as the percentage proportion of
paclitaxel loaded into the emulsion droplets (Fig. 4a) and the
amount of paclitaxel loaded per unit volume of the emulsion
(Fig. 4b). Both nanoemulsions are 20%, thus each ml of the
emulsion contains 200 mg oil plus trace amounts of surfactants
(Table 1).
Fig. 4a shows that drug loading efﬁciency was dependent on
nanoemulsion composition and drug concentration. In the
Clinoleic nanoemulsions, 70.4 3.5%, 80.2 4.2% and 77.3 2.5%concentrations of different formulations in 96-well plates (n = 3  SD).
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concentrations of 1 mg/ml, 3 mg/ml and 6 mg/ml respectively
(Fig. 4a). This means that loading efﬁciency of the drug
signiﬁcantly increased (P < 0.05) upon increasing the drug
concentration from 1 mg/ml to 3 mg/ml, however, no increase in
loading efﬁciency was seen when 6 mg/ ml was compared with
3 mg/ml (Fig. 4a). When compared with the Clinoleic emulsion, the
Intralipid nanoemulsion offered lower drug loading efﬁciencies,
regardless of paclitaxel concentration (Fig. 4a). This is contrary to
our observation using the antifungal drug amphotericin B loaded
into the same emulsions, where the Intralipid accommodated
greater drug proportions (approx. 90% of the drug) than the
Clinoleic nanoemulsion (around 80% of the drug was successfully
loaded) (Nasr et al., 2012), indicating that loading efﬁciency
depends not only on nanoemulsion formulation but also on drug
physicochemical properties. Moreover, the loading efﬁciency in the
Intralipid decreased when higher paclitaxel concentrations were
used (P < 0.05) (Fig. 4a). The loading efﬁciencies in the Intralipid
emulsion were 57.38  4.7%, 52.5  5.6% and 44.2  3.1% for the
1 mg/ml, 3 mg/ml and 6 mg/ml formulations respectively (Fig. 4a).
When considering the dose of paclitaxel loaded into the
droplets per 1 ml of the nanoemulsion dispersion, using the
Clinoleic emulsion, this was 0.704  0.035, 2.46  0.126 and
4.63  0.15 mg/ml for paclitaxel having initial concentrations of
1, 3 and 6 mg/ml respectively (Fig. 4b). For the Intralipid
nanoemulsions, the drug loaded was 0.57  0.047, 1.57  0.17 and
2.65  0.19 mg/ml for paclitaxel having initial concentrations of 1,
3 and 6 mg/ml respectively (Fig. 4b). Thus, unlike loading
efﬁciency, the dose loaded per unit volume of the emulsion
increased with increasing the paclitaxel concentration; however,
higher doses of the drug pre unit volume, were loaded in the
Clinoleic nanoemulsions. If no nanoemulsions were used, less than
0.1 mg/ml of paclitaxel can be dissolved in aqueous phase (Konno
et al., 2003), indicating that the use of nanoemulsions was highly
advantageous at providing paclitaxel formulations that have
potential for therapeutic administration.
The solubility of paclitaxel in soybean oil has been reported to
be around 0.18 mg/g (Surapaneni et al., 2012). The lipid phase of the
Intralipid emulsion comprises mainly soybean oil while the lipid of
the Clinoleic emulsion is olive oil (80%) and soybean oil (20%)
(Table 1). Also, the Clinoleic emulsion has the surfactant sodium
oleate (which is not one of the Intralipid’s constituents; Table 1).
These differences could explain the higher loading of paclitaxel in
the Clinoleic nanoemulsion compared to the Intralipid preparation
(Fig. 4). However, recent studies have reported that there was no
signiﬁcant difference in solubility of paclitaxel between both olive
oil and soybean oil (Choudhury et al., 2014b), possibly suggesting
that sodium oleate might be responsible for enhancing the loading
of the drug in the Clinoleic emulsion (Table 1). More investigations
are needed in the future to further understand the higher loading
efﬁciency of paclitaxel in the Clinoleic compared to the Intralipid
emulsion.
3.5. Tissue culture and cytotoxicity studies
Using a range of seeding densities the percentage growth of
SVG-P12 and U87-MG cells were investigated, and the seedingTable 2
IC50 (nM) of paclitaxel-loaded nanoemulsions, paclitaxel and PLL against SVG-
Formulation IC50 Value (nM)  SD for SVG
PLL 215  32.4 
Paclitaxel 119.5  12.2 
Intralipid with Paclitaxel 1014.2  132 
Clinoleic with Paclitaxel 1528.2  180 density of 105 was used in tissue culture experiments because this
seeding density was demonstrated to cause the highest cell growth
rate compared to 103 and 104 cells per well (data not shown). Free
paclitaxel was solubilised in cell culture medium using traces of
dimethylsulfoxide (DMSO) (up to 0.3%). According to Da Violante
et al. (2002) DMSO at concentrations of up to 10% did not produce
any signiﬁcant cytotoxicity.
In the cytotoxicity experiments, dextran was used as a negative
control whilst PLL was employed as a positive control. Intralipid
and Clinoleic formulations of paclitaxel were used and compared
also against other negative controls, namely, drug-free nano-
emulsions.
Drug-free Clinoleic and Intralipid nanoemulsions had no toxic
effect towards both cell lines (Fig. 5). This might be attributed to
the presence of biocompatible materials in the emulsions
(Table 1). Dextran had a similar effect to that of the emulsions
(Fig. 5). Paclitaxel alone was highly cytotoxic and killed more than
95% of the cells, with no evidence of discrimination between glial
and glioma cells, suggesting that the drug in absence of
nanoemulsions is not selective in suppressing cellular growth
(Fig. 5).
When Intralipid loaded with paclitaxel was applied on the cells,
the viability decreased to 26.04% for the SVG-P12 cells and to
21.29% for the U87-MG cells, demonstrating lower but not
signiﬁcant (P > 0.05) ability to kill the U87-MG cells than paclitaxel
alone (Fig. 5). It is possible that the Intralipid emulsion has formed
a barrier between paclitaxel and the cells, resulting in slower
release (data not shown), hence; lower cell toxicity as compared to
the paclitaxel alone. By contrast, when the Clinoleic loaded with
paclitaxel was used, the viability decreased to 34.57% for the SVG-
P12 cells (Fig. 5a) and to as low as 6.4% for the U87-MG cells
(Fig. 5b), i.e. Clinoleic loaded with paclitaxel has a signiﬁcantly
lower (P < 0.05) cytotoxicity towards SVG-P12 than that of free
Paclitaxel, indicating a higher level of selectivity of paclitaxel in the
Clinoleic emulsion against the malignant cells. Cancerous cells are
known to divide faster than normal cells; hence their intake of
nutrients is faster (Miller and Perry, 2007); this might explain the
reason behind the selectivity of the emulsions towards the
cancerous cells (Fig. 5). However, the better selectivity of the
Clinoleic nanoemulsion compared with that of the Intralipid
suggests that olive oil or sodium oleate might have further
enhanced the targeting properties of this formulation towards the
U87-MG cells (Table 2). Further studies are required to investigate
the uptake of nutritive materials by cancerous cells.
Table 2 shows that the IC50 values were highly dependent on
formulation for SVG-P12 cells (P < 0.05) as the IC50 of Clinoleic
with Paclitaxel was signiﬁcantly higher (P < 0.05) than that of
Intralipid with Paclitaxel and both were signiﬁcantly higher
(P < 0.05) than paclitaxel. Paclitaxel alone had the lowest IC50,
indicating that the free drug has higher toxicity than the drug in
nanoemulsions since much larger doses of drug in nanoemulsions
were needed to kill 50% of the cells (Table 2). The reduced
cytotoxicity of paclitaxel loaded to both nanoemulsions as
compared to free paclitaxel might be attributed to slow drug
release from nanoemulsions (data not shown). The slower release
proﬁle of paclitaxel is already established for nanoemulsion
(Choudhury et al., 2014a; Ma and Mumper, 2013)P12 and U87-MG cells. (n = 3  SD).
-P12 cells IC50 Value (nM)  SD for U87-MG cells
197  25.6
65.4  10.1
808.2  151.5
286.7  65.1
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Licensed parenteral nutrition nanoemulsions, Clinoleic1 and
Intralipid1were successfully loaded with the poorly water-soluble
anticancer drug paclitaxel. Droplet size of the paclitaxel-loaded
emulsions increased compared to drug-free formulations but was
still below 300 nm. The Polydispersity Index (PI) results indicated
that all the nanoemulsion formulations (Clinoleic and Intralipid)
were homogeneous, regardless of paclitaxel concentration in the
emulsions. However, the Clinoleic formulations demonstrated
slightly higher pH, greater negative zeta potential values and
higher loading efﬁciencies. More studies are necessary to explain
the high efﬁciency of Clinoleic formulations compared to that of
Intralipid. Both paclitaxel-loaded emulsions showed concentra-
tion-dependent cytotoxicity against both U87-MG cell and SVG-
P12 with the greater selectivity of the Clinoleic nanoemulsion
compared with the Intralipid towards cancer cells. The results
suggest that parenteral nutrition lipid nanoemulsions are able to
act as potential nanocarriers of poorly water-soluble anticancer
drugs (e.g. paclitaxel). Early studies using alkylating anticancer
agents loaded into Intralipid emulsion reported the suitability of
the resultant delivery systems for human administration following
investigations on around 100 patients (Fortner et al., 1975). Thus,
this work has introduced a potentially cost-effective way of
delivering paclitaxel, that can be prepared relatively simply from
sterile licensed components in a hospital pharmacy close to the
patient, with potential for application in the treatment of cancer.
Further in vivo studies are required to validate this hypothesis.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
ijpharm.2016.04.027.
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